DiabetologyNews.net

Diabetology Xagena

Search results for "Empagliflozin"

The results of a 78-week phase III clinical trial of the investigational agent Empagliflozin as add-on to basal Insulin in adults with type 2 diabetes ( T2D ), presented at the American Diabetes Assoc ...


The results of a 24-week phase III clinical trial, which showed that treatment with the investigational compound Empagliflozin as monotherapy produced statistically significant reductions in HbA1c ver ...


The results of two phase III 24-week clinical trials of the investigational agent Empagliflozin added to Metformin with and without the addition of sulfonylurea, in people with type 2 diabetes ( T2D ) ...


The results of a 52-week phase III clinical trial of Empagliflozin, presented at the American Diabetes Association ( ADA ) 73rd Scientific Sessions, showed statistically significant reductions in HbA1 ...


The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


Diabetes mellitus is a leading cause of chronic kidney disease ( CKD ) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macr ...


Empagliflozin ( Jardiance ) has significantly reduced the risk of the combined endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 14% when added to standard of ca ...


Positive top-line results from EMPA-REG OUTCOME were announced. This is a long-term clinical trial investigating cardiovascular ( CV ) outcomes for Jardiance ( Empagliflozin ) in more than 7,000 adult ...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in people with type 2 diabetes with establis ...


New analyses have shown risk reductions were consistent across age groups for cardiovascular outcomes, including cardiovascular death, with Empagliflozin ( Jardiance ) compared with placebo when added ...